Elanco’s monoclonal antibody treatment boosts puppy survival rates

USA – New data from Elanco Animal Health reveals that its Canine Parvovirus Monoclonal Antibody (mAb) treatment has significantly improved puppy survival rates, easing the operational strain on veterinary clinics. 

The first and only USDA-conditionally approved treatment for canine parvovirus, Elanco’s CPMA treatment has reportedly saved thousands of puppies in its first year, transforming the fight against this deadly virus.

Canine parvovirus, which affects more than 330,000 puppies annually, carries a mortality rate of up to 91% without supportive care. In response, Elanco launched CPMA, and its impact has been profound. 

Real-world data demonstrates that 93% of puppies treated with CPMA survived, with the treatment also reducing hospital stays by an average of 1.87 days. 

Additionally, the treatment has alleviated stress within veterinary clinics, with 92% of veterinarians reporting improved clinic operations and 90% expressing satisfaction with the treatment’s integration into their protocols.

Bobby Modi, Executive Vice President of U.S. Pet Health at Elanco, highlighted the company’s mission to save 1 million puppies by 2030, with the first year already showing significant progress. 

“We are proud that thousands of puppies, including Cookie, Mono, and Luna, have been saved,” Modi noted, emphasising the treatment’s role in transforming care for puppies battling parvovirus.

Veterinary professionals have lauded the CPMA treatment for its ability to enhance clinic efficiency and improve patient outcomes. 

Dr Jennifer Miller, a Technical Veterinarian at Elanco, explained that the treatment saves puppies and reduces the immense pressure on veterinary staff.

“Our recent data proves that CPMA is giving both puppies and clinic staff a new lease on life,” she said.

Elanco’s broader “Defend Puppies. Defeat Parvo” campaign includes the Parvo Defenders Task Force and ParvoTrack, an innovative online tool that allows pet owners and veterinarians to track parvovirus outbreaks in real-time.

With 900 cases already reported and over 7,000 pet owners signed up for alerts, the initiative aims to enhance public awareness and response to parvovirus outbreaks.

Veterinarians like Dr. Fred Metzger of VCA Metzger Animal Hospital are enthusiastic about the treatment’s impact.

“CPMA has not only improved survival rates but also eased the workload in our clinic,” Metzger stated. 

He recommended the treatment to fellow veterinarians, citing its transformative effect on patient outcomes and clinic operations.

Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE.